Quick Takeaways
- ABG Management Ltd. filed SCHEDULE 13G/A for Ceribell, Inc. Common Stock, $0.001 par value per share (CBLL).
- Disclosed ownership: 4.6%.
- Date of event: 09 Dec 2024.
ABG Management Ltd. - 09 Dec 2024 SCHEDULE 13G/A Report for Ceribell, Inc. Common Stock, $0.001 par value per share (CBLL)
- Filing Manager
- ABG Management Ltd.
- Reporting Manager
- ABG WTT-Ceribell Limited
- Symbol
- CBLL
- Shares outstanding
- 36,766,674 shares
- Disclosed Ownership
- 1,691,267 shares
- Ownership
- 4.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 11 Dec 2025, 15:12:13 UTC
- Date of event
- 09 Dec 2024
- Next filing
- 02 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ABG Management Ltd. disclosed 4.6% ownership in Ceribell, Inc. Common Stock, $0.001 par value per share (CBLL) on 09 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 11 Dec 2025, 15:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (11)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ABG WTT-Ceribell Limited | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Kevin Reilly | Kevin Reilly, Director | |
| ABG V-Ceribell Limited | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Kevin Reilly | Kevin Reilly, Director | |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 4.6% | 1,691,267 | 0 | 1,691,267 | By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general p | Fan Yu, Director | |
| ABG Global Life Science Capital Partners V GP, L.P. | 4.6% | 1,691,267 | 0 | 1,691,267 | By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu | Fan Yu, Director | |
| ABG Global Life Science Capital Partners V GP Limited | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Fan Yu | Fan Yu, Director | |
| Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | 4.6% | 1,691,267 | 0 | 1,691,267 | By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its gener | Fan Yu, Director | |
| ABG-WTT Global Life Science Capital Partners GP, L.P. | 4.6% | 1,691,267 | 0 | 1,691,267 | By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu | Fan Yu, Director | |
| ABG-WTT Global Life Science Capital Partners GP Limited | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Fan Yu | Fan Yu, Director | |
| ABG Management Ltd. | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Fan Yu | Fan Yu, Director | |
| Ally Bridge Group (PE) LLC | 4.6% | 1,691,267 | 0 | 1,691,267 | By: ABG Management Ltd., its managing member, By: /s/ Fan Yu | Fan Yu, Director | |
| Fan Yu | 4.6% | 1,691,267 | 0 | 1,691,267 | By: /s/ Fan Yu | Fan Yu |